

## ~~Suzhou Industrial Park promotes high-quality development of the biopharmaceutical and health industries with open innovation~~ **Promotes High-Quality Development of the Biopharmaceutical and Health Industries with Open Innovation**

In recent years, Suzhou Industrial Park (SIP) has actively served the new development pattern, adhered to the orientation of high-level open innovation, developed new quality productive forces according to local conditions, and promoted high-quality development of industries industrial development. To promote boost investment in the biopharmaceutical and health industries, SIP made conducted in-depth analysis with focus focusing on the industry direction, carried out executed targeted investment promotion promotions, and strived to gather global innovation resources, optimize the industrial ecology, get

~~a better understanding of~~ **better understand** the development needs of enterprises, and create a world-class business environment through institutional openness. In the process of promoting the negotiation and implementation of projects such as Roche, SIP established dedicated teams ~~to provide seamlessly connection~~ **that provided seamless connections** and targeted services. It facilitated projects such as the mutual recognition of regulatory standards for the first imports of bovine serum albumin between China and Germany, as well as the import and long-term management mechanism ~~offer~~ special biopharmaceutical items.

~~Next~~ **Going forward**, SIP will continue to introduce and cultivate advanced medical, pharmaceutical, and health projects, carry out pilots for open innovation throughout the entire industry chain, and strive to build a world-class pacesetter ~~of~~ **in** **the** biopharmaceutical industry of open innovation.

SIP has attracted a group of leading and high-quality innovative enterprises such as Roche and Johnson & Johnson, which represent advanced international and domestic advanced levels, to ~~make investment~~invest for the first time or increase their investment in SIP, and launch their products ~~at~~in the global market simultaneously, thereby accelerating the formation of a medical and pharmaceutical industry cluster with international competitiveness.

~~As of~~By the end of 2023, SIP housed more than 2,000 biopharmaceutical and health enterprises, with an industrial output value of 152.3 billion yuan. Among the top 20 global medical device companies, 11 have invested in SIP, bringing the park the ~~laurel~~honor of the United Nations' Investment Promotion Awards 2023 (the only winner of its kind in China).-